Van Lanschot Kempen Logo
  • Home
  • Solutions
  • News & knowledge
  • About us
Jan 2014
genmab
Joint lead manager
USD 998 million
Accelerated bookbuild offering

Genmab

Genmab is a Danish listed biotech company specialising in differentiated human antibody therapeutics for the treatment of cancer

  • Genmab raised new capital to fund the further development of in-house drug candidate HuMax-Tissue Factor-ADC and other programs
  • Kempen & Co was engaged as Joint Lead Manager and supported the company in one of the largest European Life Sciences ECM transactions of the past year

Fully focused on your future

Private Banking

  • Offices
  • Business professionals
  • Executives
  • Doctors
  • Entrepreneurs
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions


Investment Management


Investment Banking



© Van Lanschot Kempen 2022
Security
Privacy & cookies
Disclaimer